Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Horning

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Best Practice & Research. Clinical Haematology|June 11, 2011
Perspective of clinical research in follicular NHL: interaction between science and industryGregg Fine, Sandra Horning
Hematology. American Society of Hematology. Education Program|November 10, 2001
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of OptionsFernando Cabanillas, Sandra Horning, Mark Kaminski, et al.
Cancer|June 2, 2007
Non-Hodgkin lymphoma of the breastKristen Ganjoo, Ranjana Advani, M Rajan Mariappan, et al.
Hellenic Journal of Nuclear Medicine|December 17, 2008
(18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?Andrei Iagaru, Yingbing Wang, Carina Mari, et al.
Archives of Dermatology|September 24, 2004
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patientsDavid P Beynet, Sue A Wee, Steven S Horwitz, et al.
Journal of Hematology & Oncology|July 9, 2013
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)Daniel R Greenwald, Hailun Li, Selina M Luger, et al.
Radiation Oncology (London, England)|January 21, 2012
Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's diseaseDiane Tseng, Leelanand P Rachakonda, Zheng Su, et al.
British Journal of Haematology|October 14, 2009
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)Dita Gratzinger, Ranjana Advani, Shuchun Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphomaJohn P Leonard, Brian K Link, Christos Emmanouilides, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Best Practice & Research. Clinical Haematology|June 11, 2011
Perspective of clinical research in follicular NHL: interaction between science and industryGregg Fine, Sandra Horning
Hematology. American Society of Hematology. Education Program|November 10, 2001
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of OptionsFernando Cabanillas, Sandra Horning, Mark Kaminski, et al.
Cancer|June 2, 2007
Non-Hodgkin lymphoma of the breastKristen Ganjoo, Ranjana Advani, M Rajan Mariappan, et al.
Hellenic Journal of Nuclear Medicine|December 17, 2008
(18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?Andrei Iagaru, Yingbing Wang, Carina Mari, et al.
Archives of Dermatology|September 24, 2004
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patientsDavid P Beynet, Sue A Wee, Steven S Horwitz, et al.
Journal of Hematology & Oncology|July 9, 2013
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)Daniel R Greenwald, Hailun Li, Selina M Luger, et al.
Radiation Oncology (London, England)|January 21, 2012
Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's diseaseDiane Tseng, Leelanand P Rachakonda, Zheng Su, et al.
British Journal of Haematology|October 14, 2009
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)Dita Gratzinger, Ranjana Advani, Shuchun Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphomaJohn P Leonard, Brian K Link, Christos Emmanouilides, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Pageof 2